Home
My Account
About Us
Forum
Contact us
الواجهة العربية
epharmaweb.com
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz
Newsletter

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



Dostinex

Main

You must sign in to use this servcie


Feedback - Please use the form below to send your query or comment

You must sign in to use this servcie

Username:
Password:

Info

Indications:

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenoma

Contraindications:

Cabergoline tablets are contraindicated in patients with * Uncontrolled hypertension or known hypersensitivity to ergot derivatives. * History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders (see PRECAUTIONS, Fibrosis)

Adverse reactions:

The safety of Cabergoline tablets has been evaluated in more than 900 patients with hyperprolactinemic disorders. Most adverse events were mild or moderate in severity. In a 4 week, double-blind, placebo-controlled study, treatment consisted of placebo or Cabergoline at fixed doses of 0.125, 0.5, 0.75, or 1 mg twice weekly. Doses were halved during the first week. Since a possible dose-related effect was observed for nausea only, the four Cabergoline treatment groups have been combined. The incidence of the most common adverse events during the placebo-controlled study is presented in the following table.

Interactions:

Cabergoline should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.

Warnings:

Valvulopathy Postmarketing cases of cardiac valvulopathy have been reported in patients receiving Cabergoline. These cases have generally occurred during long-term administration of high doses of Cabergoline (> 2mg/day) used for the treatment of Parkinson’s disease. Rare cases have been reported associated with short-term treatment (< 6 months) or in patients receiving lower doses for the treatment of hyperprolactinemia. Physicians should use the lowest effective dose of Cabergoline for the treatment of hyperprolactinemia and should periodically reassess the need for continuing therapy with Cabergoline. In addition, patients receiving long-term treatment with Cabergoline should undergo periodic reassessment of their cardiac status, and echocardiography should be considered. Any patient who develops signs or symptoms of cardiac disease, including dyspnea, edema, congestive heart failure, or a new cardiac murmur, while being treated with Cabergoline should be evaluated for possible valvulopathy. Cabergoline should be used with caution in patients who have hemodynamically significant valvular disease or have been exposed to other medications associated with valvulopathy. Pregnancy Dopamine agonists in general should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia, eclampsia, and post partum hypertension, unless the potential benefit is judged to outweigh the possible risk. General Initial doses higher than 1 mg may produce orthostatic hypotension. Care should be exercised when administering Cabergoline with other medications known to lower blood pressure. Postpartum Lactation Inhibition or Suppression Cabergoline tablets are not indicated for the inhibition or suppression of physiologic lactation. Use of bromocriptine, another dopamine agonist for this purpose, has been associated with cases of hypertension, stroke, and seizures. Hepatic Impairment Since Cabergoline is extensively metabolized by the liver, caution should be used, and careful monitoring exercised, when administering Cabergoline to patients with hepatic impairment. Fibrosis As with other ergot derivatives, pleural effusion or pulmonary fibrosis have been reported following long-term administration of Cabergoline. Some reports were in patients previously treated with ergotinic dopamine agonists. Cabergoline should not be used in patients with a history of, or current signs and or clinical symptoms of, respiratory or cardiac disorders linked to fibrotic tissue. Following diagnosis of pleural effusion or pulmonary fibrosis, the discontinuance of Cabergoline has been reported to result in improvement of signs and symptoms. Erythrocyte sedimentation rate (ESR) has been found to be abnormally increased in association with pleural effusion/fibrosis. Chest x-ray examination is recommended in cases of unexplained ESR increases to abnormal values. Serum creatinine measurements can also be used to help in the diagnosis of fibrotic disorder. Psychiatric Pathological gambling, increased libido, and hypersexuality have been reported in patients treated with dopamine agonists including Cabergoline. This has been generally reversible upon reduction of the dose or treatment discontinuation (see Postmarketing Surveillance Data

Form:

TABLET

Dosage and Administration

You must sign in to use this servcie

Technical Description

You must sign in to use this servcie






Forgot your password


sign up

Consultants Corner

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr. Talal Sabouni

Dr. Talal Sabouni UROLOGY AND KIDNEY TRANSPLANT

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist
Poll

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details